Medicus Pharma to acquire Antev, expanding pipeline with potentially first-in-class prostate treatment

• click to rate

  Posted by Two Blokes Apr 28 - Filed in Stock - 3 views
  
  Medicus Pharma (NASDAQ:MDCX) announced that it has entered into a binding letter of intent to acquire Antev, a clinical-stage biotechnology firm developing a first-in-market product Teverelix for acute urinary retention (AUR) and high cardiovascular risk prostate cancer.   Teverelix, a next-generation GnRH antagonist, targets the prevention of recurrent AUR in males aged 45 years and older with benign prostate hyperplasia.